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ORIGINAL RESEARCH REPORT
Long-Term Hematopoietic Engraftment
of Congenic Amniotic Fluid Stem Cells After
in Utero Intraperitoneal Transplantation
to Immune Competent Mice
Panicos Shangaris,1,2,* Stavros P. Loukogeorgakis,2,* Michael P. Blundell,4
Eleni Petra,2 Steven W. Shaw,1–3 Durrgah L. Ramachandra,1,2 Panagiotis Maghsoudlou,2
Luca Urbani,2 Adrian J. Thrasher,4 Paolo De Coppi,2,{ and Anna L. David1,5,{
Clinical success of in utero transplantation (IUT) using allogeneic hematopoietic stem cells (HSCs) has been limited
to fetuses that lack an immune response to allogeneic cells due to severe immunological defects, and where
transplanted genetically normal cells have a proliferative or survival advantage. Amniotic fluid (AF) is an autologous
source of stem cells with hematopoietic potential that could be used to treat congenital blood disorders. We
compared the ability of congenic and allogeneic mouse AF stem cells (AFSC) to engraft the hematopoietic system of
time-mated C57BL/6J mice (E13.5). At 4 and 16 weeks of age, multilineage donor engraftment was higher in
congenic versus allogeneic animals. In vitro mixed lymphocyte reaction confirmed an immune response in the
allogeneic group with higher CD4 and CD8 cell counts and increased proliferation of stimulated lymphocytes. IUT
with congenic cells resulted in 100% of donor animals having chimerism of around 8% and successful hematopoietic
long-term engraftment in immune-competent mice when compared with IUT with allogeneic cells. AFSCs may be
useful for autologous cell/gene therapy approaches in fetuses diagnosed with congenital hematopoietic disorders.
Keywords: amniotic fluid stem cells, prenatal therapy, in utero stem cell transplantation
Introduction
In humans, successes with in utero transplantation (IUT)using allogeneic hematopoietic stem cells (HSCs) has been
limited to fetuses with severe immunologic defects, where
there is an effective lack of immune response to the transplanted
allogeneic cells, andwhere these genetically normal cells have a
proliferative advantage [1]. Mesenchymal stem cells (MSCs)
appear to be less immunogenic than their hematopoietic coun-
terparts. They engraft after IUT in human fetuses with osteo-
genesis imperfecta in an allogeneic setting [2] and reduce
fracture rate in a mouse model of the disease [3]. However,
attempts to treat congenital hematological diseases such as
sickle cell disease [4] with in utero HSC transplantation have
been unsuccessful, even where a suitably matched donor has
been available.
Studies in mice suggest that the immune barrier to alloge-
neic in utero HSC transplantation may be stronger than previ-
ously thought [5,6]. Maternal antibodies also play an important
role [7,8]. Even though induction of tolerance for allogenic
cells could be a promising approach [9], transplantation of
autologous progenitor cells, which have been corrected for
congenital disease, could avoid the fetal immune barrier.
Amniotic fluid (AF) is a source of ckit+ stem cell-like
progenitors with hematopoietic potential that are characterized
by long-term self-renewal and the ability to differentiate into
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all three lineages [10–13]. AF can be collected using a clin-
ically safe ultrasound guided method, currently used for pre-
natal diagnosis of congenital disease. AF stem cells (AFSCs)
from mice and humans can be expanded as MSCs without
feeder layers [14], are not tumorigenic, and retain long telo-
meres and a normal karyotype for over 250 population dou-
blings [15,16] Their potential for gene transfer [17] prenatal
and postnatal therapy is enormous [18,19]. We have previ-
ously demonstrated the potential of AFSCs for autologous
IUT in pregnant sheep, a clinically relevant large animal
model whereby mesenchymal or hematopoietic selected
AFSCs engrafted after autologous transplantation in utero
[20,21]. We hypothesize that AF-derived stem cells could be
used as an autologous source of cells for the treatment of
congenital hematological disease [19].
Here, we studied the engraftment and immune response to
cKit+Lin- AF cells after congenic and allogeneic IUT in
mice using intraperitoneal injection, a clinically relevant
delivery method that has been safely used in the first tri-
mester for IUT in humans [1].
Materials and Methods
Animal care
All the animals used were sourced from Harlan Company
and were housed in a single cage after plugging. Vaginal
plugs were checked by the animal technicians and the first
day of gestation was considered the day after the plug was
found. The dams were given wet food after surgery and
closely monitored for the first 7 days after the procedure.
The animal experiments were done according to the project
license PPL No: 70/7408 and Animals [Scientific Proce-
dures] Act 1986 and the NC3Rs ARRIVE guidelines 2013.
Cell sources
Mouse AFSCs (mAFSC) were isolated by lineage deple-
tion with magnetic separation (Miltenyi Biotec), followed by
CD117 separation using flow cytometry as described [13].
Similarly bone marrow (BM) stem cells were isolated from
mouse adult BM using published techniques for lineage de-
pletion with magnetic separation (Miltenyi Biotec) followed
by separation using flow cytometry and Sca1 antibody. Lin-/
Sca1+ cells were used for BM transplantation [8,22]. Fetal
liver (FL) stem cells were used for comparison. These were
isolated from E13.5 fetuses by mechanical dissociation of the
FL and lineage depletion by magnetic separation. The cells
were characterized using flow cytometry to demonstrate the
specific cell populations used for the control experiments and
IUT (Supplementary Fig. S1; Supplementary Data are avail-
able online at www.liebertpub.com/scd). To mimic autolo-
gous IUT, cKit+/lin-, congenic mAFSC, were isolated at
E13.5 from B6.SJL-Ptprca Pepcb/BoyJ dams (CD45.1; MHC
class I: H2-Kb+). For allogeneic IUT, mAFSC were isolated
from fetuses of BALB/cJ (CD45.2+; MHC class I: H2-Kd+)
dams. After confirming death, the abdomen of the mouse was
cleaned and carefully opened with sterile scissors and the
uterine horns were removed intact into a sterile petri dish. The
uterus was irrigated with phosphate-buffered saline (PBS) to
remove maternal blood. Using sterile scissors, each amniotic
sac was carefully dissected from the surrounding uterus and
washed with PBS. The amniotic sac was then punctured using
fine sterile scissors and the whole AF (about 50mL) was
collected into a 20mL falcon tube after passing through a
50mL nylon filter. Only clear AF was collected. Obviously
blood stained AF was discarded to exclude maternal or pla-
cental contamination as described [13].
The clear AF from all fetuses from up to three dams was
pooled together. Red Blood Cell lysis was used to remove
any remaining red blood cells and to prevent any fetal or
maternal blood contamination. The cells were then washed
with PBS three times and counted. IUT was performed at
E13.5 into C57BL/6 (CD45.2/H-2KD) dams time mated
with C57BL/6 (CD45.2/H-2KD) male mice. There were at
least three different dams transplanted in three biologically
independent experiments in each group.
In utero stem cell transplantation
Mouse IUT as performed at E13.5 under general an-
esthesia. After clipping the abdominal wall, cleaning, and
sterile draping, the abdomen was opened by a midline inci-
sion to reveal the two pregnant uterine horns. At laparotomy,
the liver of each embryo was identified through the trans-
parent uterine wall. Prepared mAFSCs or Congenic BM Stem
Cells in 20mL (1· 104 or 5· 104 cells) of PBS were injected
into the peritoneal cavity inferior to the liver of each embryo
using a 33-gauge needle attached to a digital syringe
(Hamilton, Switzerland). All embryos of each litter were in-
jected. The abdomen was closed in two layers using 6.0 Vi-
cryl Rapide suture (Ethicon). The skin layer was closed using
the subcuticular method. The dams were transferred to a
warm cage (28C) for initial recovery, given wet food and
closely monitored postoperatively.
After spontaneous delivery at E20–E21 day of gestation,
treated pups were cross-fostered to CD1 after birth, to avoid
maternal cannibalism and maternal antibody response to the
transplanted cells [8,23,24]. They underwent a scheduled
postmortem examination at 4 or 16 weeks after birth, where
blood and tissue were isolated for flow cytometry, in vitro
mixed lymphocyte reaction (MLR) histology, and qPCR as
described below.
Blood collection
Blood was collected under terminal anesthesia, induced
by injecting tribromoethanol (0.8mL of 1.25%; Avertin
Sigma- Aldrich) solution into the peritoneal cavity. About
0.5–1mL of blood was collected into 0.5mL EDTA tubes
by cardiac puncture using a preheparinized 26G syringe.
Tissue isolation
At scheduled postmortem examination, the animals were
culled and the thoracic and abdominal cavity exposed by a
midline incision. The organs (spleen, kidneys, heart, lungs,
and liver) were removed using sterile forceps and scissors
and placed in microtubes (1.5mL Safe-Lock; Eppendorf)
for RNA isolation. Small amounts of tissue were collected
into sterile PBS for flow cytometry analysis. Also, tissue
sections were fixed in 4%PFA for histological analysis. For
BM collection, the muscle tissue was cleared from the
femoral and long tibia bones; the epiphyses were removed
and placed in microtubes (1.5mL Safe-Lock; Eppendorf).
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Blood and tissue staining for flow cytometry
The tissues (liver and spleen) were initially mechanically
dissociated using a 40mm nylon filter. The BM was flushed
out of the long bones during PBS and 1mL syringe with
26G needle. The sampled blood or dissociated tissues were
added to 5mL RBC Lysis Buffer in conical tubes (15mL,
Falcon; BD Biosciences). These were then centrifuged at
300 g for 5min. The lysate was aspirated and resuspended in
100 mL Flow Cytometry PBS, PH7.2, with 0.5% of Bovine
Serum Albumin (BSA) (SB buffer). One mL of the conju-
gated antibody was then added and incubated at 4C for
15min. After 15min the lysate was washed with 1–2mL of
SB buffer and spun for 5min at 300 g. The supernatant was
discarded. The pellet was transferred to a flow cytometry
tube (5mL; BD Biosciences) after resuspension with 500mL
of SB Buffer and then analyzed using the flow cytometry
analyzer LSR II (BS Biosciences).
For the detection of the transplanted cells a specific anti-
body against the donor cells was used as follows: for con-
genic experiments, CD45.1 (Fig. 2A, C, E) and for allogenic
experiments H-2Kd (Fig. 2B, D, F). The results are presented
as the number of positive cells for the donor antibody out of
the total number of CD45+ cells (Supplementary Fig. S2 for
the gating strategy used). Animals injected with PBS were
used as flow cytometry controls. In the erythroid differenti-
ation assay, mouse embryonic fibroblasts were used as neg-
ative controls. For the lineage analysis, the lineage-specific
antibodies CD3, CD11b, B220, Gr1, and Ter-119 (Miltenyi
Biotec, Germany) were used. The hematopoietic colonies
were liquefied usingRPMI 1640 (ThermoFisher Scientific) and
stainedwith donormarkers before flowcytometry.The viability
dye 7-Amino-Actinomycin D (7AAD) (Sigma-Aldrich) was
used to exclude dead cells from the analysis.
In vitro MLR
The in vitro MLR assay was performed as published [25],
in three different animals of each group in triplicates. For the
proliferation assays, splenocytes from recipients of congenic
and allogenic transplants were labeled with the dye carbox-
yfluorescein diacetate succinimidyl ester (CFSE; Invitrogen)
by incubating cells in CFSE (1mM; Invitrogen) in 1mL PBS
at 37C for 10min, followed by three washes in RPMI with
10% FBS.
One milliliter of medium containing labeled cells were
added to 96-well U-bottom plates at a concentration of
1,000,000 cells/mL in RPMI culture media [10% FBS,
2mM L-Glu, and 100U/mL penicillin/streptomycin (In-
vitrogen Life Sciences)]. For both groups, allogeneic and
congenic MLRs, cells from uninjected (naı¨ve) BALBc and
CD45.1 animals, unlabeled splenocytes/lymphocytes, were
irradiated (6,000 rads from a cesium source, = 60 Gy· 33
s = 1,980 s) and added to the wells for a final ratio of 1:1.
The CFSE-labeled lymphocytes from the transplant re-
cipients were incubated for 5 days (120 h) with the unla-
beled irradiated naı¨ve splenocytes/lymphocytes The cells
were washed and prepared for flow cytometry analysis by
incubation with the antibodies CD3, CD4, and CD8 (Mil-
tenyi Biotec). The viability dye 7-Amino-Actinomycin D
(7AAD) (Sigma-Aldrich) was used to exclude dead cells
from the analysis.
Erythroid differentiation
The erythroid differentiation was performed by culturing
the cells in a concentration of 100,000 cells per 1.9 cm2,
52,631 cells/cm2 in erythroid differentiation medium con-
taining 50mL stem span (Stem Cell Technologies) 10mL
FBS, dexamethasone (Sigma-Aldrich), 1mL of 100%EtOH
in 50mL of medium (20 mcg/mL medium concentration),
10mL of erythropoietin (EPO, 10 mL/mL; Sigma-Aldrich),
and 100mL of stem cell factor (SCF, 1mg/mL; Sigma-
Aldrich). The cells were plated in the erythroid medium for
a total of 5 days before flow cytometry analysis was con-
ducted for the presence of adult hemoglobin using a specific
adult hemoglobin antibody (Hb-PE; Abcam).
Semi-solid colony forming assays
The semi-solid assays were performed as per manufactur-
er’s instructions by culturing 104–105 cells expressing the
donor’s marker (CD45.1+ or H2-Kd+) per 35mm dish. The
cells were isolated from the BM of the transplant recipients or
freshly isolated AFSCs at E13.5. The cells were prepared,
washed and counted, and were added to a 5mL tube con-
taining 2.5mL of MethoCult (MethoCultGFM3434, Stem
Cell Technologies, containing Methylcellulose in Iscove’s
MDM, Fetal bovine serum, Bovine serum albumin, Re-
combinant human insulin, Human transferrin (iron-saturated),
2-Mercaptoethanol, Recombinant mouse SCF, Recombinant
mouse interleukin 3 (IL-3), Recombinant human interleu-
kin 6 (IL-6), and Recombinant human EPO. The tube was
vortexed and allowed to stand to allow bubbles to dissipate.
The cells were then dispensed into 35mm culture dishes
using a syringe and a blunt needle. The cells were incubated
for 14 days in a humidified incubator at 37C and 5% CO2.
The colonies were then counted using an inverted micro-
scope and gridded scoring dishes. The culture was liquefied
using RPMI medium (GIBCO) for further flow cytometry
processing.
Real-time PCR
The expression levels of FoxP3, TGF- b, and IL-10 was
analyzed using the SensiFAST SYBR Hi-ROX One-Step
Kit (Bioline) as per manufacturer’s instructions amplifying
10 ng template RNA. The relative expression levels in wild-
type C57BL/6J mice of Foxp3 and TGF-b were used for
normalization of results.
Relative quantification of each target gene studied was
calculated by the DDCt method on an Applied Biosystem
Step One Plus Real-Time PCR system (ThermoFisher Sci-
entific). The forward and reverse primers used can be found
in Supplementary Table S1 and they were adapted from
Singh et al. [26].
Statistical analysis
Statistical analysis used GraphPad Prism 7 with ANOVA
as the main statistical test including Bonferroni correction.
The numbers are presented as mean – SEM. To achieve a
statistically meaningful result, for each group we aimed to
have at least six mice pups in each group, born by more than
three different dams, to have more than three independent
biological replicates.
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Results
Mouse AFSC can produce hematopoietic colonies
and hemoglobin in vitro
We observed that fresh AFSCs can be reliably isolated
from mouse AF and have equal CD45 expression to mouse
FL-derived HSC and BM HSC while differing from FL-HSC
for Sca-1 expression and from BM-HSC for cKit and Sca-1
(Fig. 1A and Supplementary Fig. S2 for co-expression of
stem cell markers). AFSC cell cycle analysis demonstrated as
expected that the clear majority of cells were in GO/G1 phase
(78.53%– 3.85%), with the rest of the cells distributed in S
(9.85%– 2.21%) and G2M phase (6.51%– 0.80%) n= 3.
When cultured in semi-solid medium mAFSCs produced
hematopoietic colonies. (Fig. 1B). Further differentiation
pushed them to terminal erythrocytes with mouse hemoglobin
production at levels comparable to an adult mouse (Fig. 1C).
Congenic mouse AFSCs engraft in the immune
competent mouse in utero
Having demonstrated their hematopoietic potential in
vitro, mAFSCs were transplanted in utero to immunocom-
petent mice via intraperitoneal injection, to test their ability
to engraft long term (Fig. 1D). All embryos of each litter
were injected. After birth, pups were cross-fostered in the
day after birth. Pup survival rate was comparable between
the two groups (18 pups out of 37, 48.6%: congenic, 17 out
of 36, 47.2%: allogeneic). Immediate neonatal death was
due to maternal cannibalism seen when pups were cross-
fostered, or due to in utero fetal demise post IUT, which
occurred in approximately 30% of injected pups. (evidence
of miscarriage was seen during the postmortem analysis of
the dam that was performed after cross-fostering). There
were no pup deaths from cross-fostering up to scheduled
postmortem examination at 4 or 16 weeks.
All congenic transplanted animals (18 out of 18) were
chimeric (>1% of positive donor cells among the CD45+
cells population) compared with only 29% (5 out of 17) of
the animals receiving allogeneic cells. Compared to allo-
geneic transplantation of AFSCs (Ckit+/Lin-) and Congenic
BM (Sca1+/Lin-), autologous transplantation of AFSCs re-
sulted in far higher levels of engraftment in animals ana-
lyzed at 4 or 16 weeks, in the blood, BM, and spleen
(Fig. 1E, F). Increasing the number of injected cells by
fivefold (5 · 104) did not improve engraftment of allogeneic
AFSCs; indeed, engraftment was even lower (Fig. 1E).
Mouse AFSCs show hematopoietic
multilineage engraftment
Donor-recipient balanced multilineage long-term engraft-
ment was confirmed in the BM of recipient groups at 16 weeks
postnatal by characterization of donor cell marker expression
(CD45.1 and H2Kd) using donor-specific antibody with he-
matopoietic lineage markers CD3, B220, CD11b, Gr1, and
Ter-119 i.e., cells double positive for the donor specific and
lineage marker (Fig. 1G).
Cells positive for donor markers from 16-week postnatal
recipient BM were selected using FACS and cultured in a
semi-solid medium for 2 weeks. The culture confirmed the
presence of hematopoietic colonies from blood lineages:
erythroid & myeloid (Fig. 1H). There were a higher number
of CFU-GM (Colony Forming Unit, Granulocyte–Monocyte)
and CFU-GEMM (Colony Forming Unit, Granulocyte, Ery-
throcyte, Monocyte, Megakaryocyte) colonies generated from
BM of animals injected with congenic AFSCs when com-
pared with BM of animals injected with allogeneic AFSCs.
The colonies were liquefied using flow RPMI medium and
flow cytometry analysis confirmed presence of donor cells
(CD45.1+ and H2Kd+). The liquefied colonies were also an-
alyzed using the differentiation markers CD3, B220, CD11b,
Gr1, and Ter-119 (Supplementary Fig. S3). The results show
the presence of donor cells and markers of terminal hema-
topoietic differentiation in the liquefied colonies.
Absent immune response to congenic but not
allogenic mouse AFSCs in transplant recipients
To further understand the reasons for the low engraftment
seen in the allogeneic recipient group we investigated the role
of the immune response to IUT. There was no difference in
FIG. 1. Amniotic fluid stem cell isolation, in utero stem cell transplantation and in vitro differentiation. (A) Flow cytometry
expression analysis (purity) of CD117, CD45 and Sca1 in the freshly isolated cells FL: CD117 (100– 0.0), CD45
(83.85 – 2.45), Sca1(65.20 – 4.4) (BM: CD117 (73.10 – 2.30), CD45 (86.80– 0.90), Sca1(69.30 – 3.5), AFSC: CD117
(95.25 – 0.95), CD45 (85.5 – 2.55), Sca1(86.95 – 1.65) There was no significant difference in CD45 expression, n = 6, p = 61.
(B) Mouse AFSCs successfully produced hematopoietic colonies (CFU-GM, CFU-GEMM, BFU-E, n = 3) after 2 weeks in
semisolid medium (Methocult, M3434, stem cell technologies, Scale Bar 100mm). (C)Hemoglobin production of AFSC after
culture in a terminal erythroid differentiation medium for 5 days. BM and mouse embryonic fibroblasts were used as a control
(n = 3). (D) Study design all embryos in each litter were successfully injected, and all dams survived the surgical procedure. (E)
Engraftment (measured as percentage of donor cells in total of CD45+ cells) at 4 weeks after birth in the congenic versus the
allogeneic group in the blood (8.191 – 1.45, n = 7 vs. 1.18 – 0.37, n = 8, P < 0.05), bone marrow (8.05 – 1.96, n = 7 vs.
2.25 – 0.70, n= 8, P < 0.05), and spleen (4.67– 0.92, n = 7 vs. 0.94 – 0.23, n = 8, P< 0.05). Transplanting a fivefold higher
number of cells (5 · 104) in recipients of the allogenic group did not increase engraftment blood 0.07 – 0.02, bone marrow
0.13 – 0.11, and spleen 0.28 – 0.18, n = 6. (F) Engraftment (measured as percentage of donor cells in total of CD45+ cells) at 16
weeks in the blood (congenic AFSC 7.69– 1.55, n = 11 vs. allogenic ASFC, n= 9 1.41 – 0.52 vs. congenic bone marrow n= 4
1.47 – 1.20, P< 0.05), bone marrow (9.17– 2.94 vs. 0.60 – 1.41 vs. 1.07 – 0.26, P < 0.05), and spleen (3.69 – 0.78 vs.
0.58 – 0.17 vs. 1.13 – 0.09, P < 0.05). (G)Donor cells (CD45.1 and H2Kd) from the bone marrow at 16 weeks were positive for
all three blood lineages (% of lineage marker within CD45+ cells) (CD3, B220, CD11b, Gr1, and Ter119) and not significantly
different from the host cell populations (CD45.2 and H2Kb) (n= 3, P = 0.99). (H)After culturing the donor cells in a semisolid
differentiation medium, there was a significantly higher number of colonies in congenic versus allogenic cell sources (BFU-E
14.67 vs. 8.83 P = 0.331, CFU-GM 50.00 vs. 22.17, P < 0.05, CFU-GEMM 68.67 vs. 31.67, n = 3, P< 0.05). P-values *, and
** denote levels 0.05 and 0.01 of statistical significance accordingly. AFSC, amniotic fluid stem cell; BM, bone marrow.
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the total number of CD4 and CD8 cells present at 4 weeks in
control and autologous recipient BM, blood, and spleen, but
the total CD4 and CD8 cell numbers were far higher in the
allogenic recipient group (Fig. 2A–C). Similarly, in vitro
MLR studies showed a significantly higher rate of CD4 and
CD8 T lymphocyte proliferation in the splenocytes of the
allogeneic recipient group compared with the control and
congenic recipient group Fig. 2D and E.
In the spleen, in the congenic recipient animals the
relative expression of Foxp3 was significantly increased
(P < 0.05) (4.94 – 1.12, n = 4) while the allogenic recipient
animals had a lower mean expression (0.05 – 0.015, n = 5).
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In the congenic recipient animals, the relative expression of
Foxp3 in the BM was significantly increased (P < 0.05)
(1.71 – 0.25, n = 4) compared with allogenic recipient ani-
mals (0.035 – 0.0086, n = 5).
In the spleen, in the congenic group (3.17 – 0.53, n = 4)
the relative expression of TGF- b was significantly in-
creased (P < 0.05) versus allogenic group (0.014 – 0.0065,
n = 5). In the congenic group the relative expression of TGF-
b in the BM was significantly increased (9.46 – 0.84, n = 4)
versus allogenic animals (0.76– 0.28, n = 5).
The relative gene expression of FoxP3, TGF-b, and IL-10 at
4 weeks was higher in the thymus, spleen, and BM of congenic
compared with allogeneic recipients, suggesting a higher ac-
ceptance of the graft and lack of an immune response. There
was no significant difference in the gene expression between
allogeneic chimeric and allogenic nonchimeric recipients
(Data shown only for thymus; Fig. 2F–H).
Histological analyses
Tissues from the IUT recipient animals showed no evi-
dence of pathological changes.
Discussion
We investigated the potential barriers to the in utero en-
graftment of AFSCs in this study. We first confirmed that
stem cells can be isolated from mouse AF as previously
described [13,15] and found that most of the purified AFSCs
FIG. 2. Immune response to allogenic stem cell transplantation. (A–C) Compared with control and congenic cell transplanted
groups, therewas a significantly higher percentage of CD4 andCD8 cells per total CD45+ count in the allogenic transplanted group,
in the blood (CD4:13.57– 1.44 vs. 15.70–2.67 vs. 59.33–5.15, CD8: 12.70– 1.94 vs. 14.20– 0.73 vs. 62.37–3.77), bone marrow
(CD4:20.50– 1.42 vs. 23.43–4.94 vs. 65.67– 1.33, CD8:17.70– 0.73 vs. 21.16– 2.94 vs. 71.50–2.09), and spleen (CD4:
22.43–0.95 vs. 18.36–4.16 vs. 65.40–3.50, CD8: 19.17–1.29 vs. 22.23–4.23 vs. 74.96–2.83) There was no significant dif-
ference between the congenic and control transplanted groups (n=3,P=0.99). (D, E)T cell proliferation of recipient CSFE labeled
splenocytes stimulated with inactivated splenocytes from the donor was significantly higher in the allogenic group (CD4=
64.53%–2.28%, CD8= 60.48%–0.82%, P< 0.05) with no difference seen after stimulation in the control transplanted (CD4=
46.07%–1.61%, CD8= 12.59%–1.93%, P> 0.99) and the congenic transplanted group (CD4=48.57–2.11, CD8=13.93%–
1.94%, P> 0.99). (F) Relative gene expression of Foxp3 by qRT-PCR in the thymus was significantly higher in the congenic
compared to the allogenic chimeric animals at 4 weeks. Congenic versus allogenic chimeric (1.0 vs. 0.47, n= 8, P<0.05), congenic
vs allogenic nonchimeric (1.0 vs. 0.30, n= 4, P<0.05), congenic versus control (1.0 vs. 0.19, n=7, P<0.0001) and Allogenic
chimeric versus control animals (0.47 vs. 0.19, n=8,P<0.05). (G) Similar to Foxp3, relative gene expression of TGF-beta by qRT-
PCR in the thymuswas significantly higher in the congenic compared to the allogenic chimeric animals.Differenceswere seen in the
congenic versus control (0.90 vs. 3.7, n= 7, P<0.05), allogenic chimeric versus control (2.1 vs. 0.90, n=8, P< 0.05), congenic
versus allogenic chimeric (3.7 vs. 2.1, n=8,P= 0.0025) and congenic versus allogenic nonchimeric (3.7 vs. 1.4, n= 4,P<0.05). (H)
There was higher IL10 gene expression in the congenic group compared to other groups and the control (12.64 vs. 1.095 vs. 1.66 vs.
1.10, n= 5,P<0.05).P-values *, **, *** and **** denote levels 0.05, 0.01, 0.001 and 0.0001 of statistical significance accordingly.
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are in the G0/G1 phase of the cell cycle corresponding to a
primitive HSC with high stem cell activity [27], which are in
cell quiescence.
To ensure as much as possible that the AF was free from
contamination with maternal cells we collected the fluid
using a well-described technique [13]. First the uterus and
then the amniotic sacs were carefully washed before punc-
ture of the amniotic membrane with a sterile technique,
ensuring as far as possible that only AF was isolated from
the amniotic sac. Obviously, contaminated samples were
rejected and the fluid was then subjected to red cell lysis to
destroy any contaminating fetal or maternal red blood cells.
In our previous study, GFP expression was used to select
donor AF cells before transplantion [13]. In this study it was
not possible to use the same technique as the experimental
set up involved different mouse strains. Nevertheless, we
believe that our collection technique is robust for selecting
fetal cells. This is supported by the findings from our control
group experiments in which maternal BM-derived stem cells
were found to have minimal engraftment.
When cultured in the semi-solid medium the mouse AFSCs
produced hematopoietic colonies from all three hematopoietic
lineages, and they were capable of hemoglobin production
when cultured in an erythroid differentiation medium similarly
to BM stem cells [28]. Having demonstrated their hematopoi-
etic potential in vitro, the mouse AFSCs were used in an in
utero stem cell approach to test their ability to engraft long
term. We found that allogeneic transplantation in utero was
associated with lower rats of engraftment at 4 and 16 week time
points, when compared with autologous transplantation. This
was of interest to us, as an in utero approach is considered to be
relatively more successful at achieving engraftment through
fetal tolerance [6,9,29–32]. Injecting even higher numbers (5· )
of allogenic AFSC cells did not achieve tolerance or higher
engraftment. We ensured that there was no maternal antibody
effect postnatally by cross-fostering the pups to different dams
after birth, thus avoiding passage of antibodies through lacta-
tion. This effect has previously been described in mice and
nevertheless we cannot rule out the possibility that maternal
antibodies passed across the placental barrier following allo-
genic IUT and before birth. The lack of tolerance might also be
due to the primitive nature of the ASFC and their inability to
present in the thymus and achieve a ‘‘self’’ identity [33–35].
Due to the low engraftment seen in the allogenic trans-
planted group we studied the immune reaction using the
total number of CD4 and CD8 cells present at 4 weeks. The
presence of an immune response was confirmed by per-
forming in vitro MLR studies where splenocytes (responders)
isolated from the IUT recipient mice at 4 weeks of age
were cocultured with splenocytes from genetically identi-
cal naı¨ve donors (stimulators). The significantly higher
proliferation rate of CD4 and CD8 T lymphocytes in the
allogenic group confirmed the presence of an immune re-
sponse toward the donor cells. On the contrary, in the
congenic group the T lymphocyte proliferation was similar
to the uninjected control, which indicates that the congenic
cells did not form any significant negative antigen re-
sponse. The congenic recipients did have a tolerogenic
response though, since FoxP3, TGF-b, and IL10 gene ex-
pression were significantly higher in comparison with the
uninjected control and allogenic group when measured by
qPCR.
Multilineage long-term engraftment was confirmed in the
recipient groups by characterization of the cells expressing the
donor markers using hematopoietic lineage markers such as
CD3, B220, CD11b, Gr1, and Ter-119. We detected double
positive CD45.1 and lineage-specific cells in BM and blood,
which is an indication that mouse AFSCs can give rise to
terminally differentiated cells and integrate fully into the he-
matopoietic system. The cells were also cultured in a semi-
solid medium, which confirmed the multilineage engraftment
by the presence of hematopoietic colonies from blood lineages,
myeloid, and erythroid. The hematopoietic colonies were also
analyzed using flow cytometry, which confirmed expression of
differentiation markers [6,31]. The higher expression of FoxP3,
TGF-b, and IL-10 both centrally and peripherally in the con-
genic recipients suggests the possibility that the congenic
cells expressing the markers CD45.1 lead to a more tolerant
state toward the transplanted cells. Studies have shown that
increased FoxP3 expression is associated with self-tolerance
and tolerance to noninherited antigen [36]. In addition
CD4+CD25+FoxP3+ regulatory T cells are involved in trans-
plantation tolerance and they prevent rejection in solid organ
transplantation when co-transplanted with the allograft [37,38].
For clinical translation, we have demonstrated that HSCs
derived from the AF could be used as a source for the
treatment of congenital blood disorders. Since allogeneic
AFSCs appear to cause an immune response in mice, au-
tologous (congenic) transplantation would be preferred.
After combining gene therapy and subsequent correction
and expansion of gene-corrected AFSCs, the cells could be
given back to the same fetus with the aim to correct he-
matological or other monogenic disease before birth [17].
The multilineage engraftment we observed suggests that
these cells could reconstitute the hematopoietic system if
given in sufficient numbers. AFSC expansion while main-
taining their hematopoietic potential is an important hurdle
that will need to be overcome to provide sufficient stem
cells to cure hematopoietic disease. In addition, the safety of
gene transfer to AFSC for long-term transduction will need
to be assessed. Transplantation of induced pluripotent stem
cells from AF or other fetal sources such as chorionic villi, if
proven safe, could be another approach. The next step is to
assess the engraftment potential of AFSC after IUT using other
injection methods such as intravenous umbilical vein injection
that is also applicable to human pregnancies, and to study in
detail the immune response(s) to allogeneic and congenic
AFSC sources. Another limitation to the study is that we did
not demonstrate whether transplanted AFSCs were able to
function in vivo, for example, to produce hemoglobin, and
potentially correct a mouse model of congenital disease such as
thalassemia. Such experiments are being planned.
In conclusion, we have shown successful hematopoietic
engraftment in immune-competent mice using mouse
AFSCs. Production of hemoglobin in vitro shows that these
cells are functional, forming terminal erythrocytes. Con-
genic AFSCs appear to have a significant engraftment ad-
vantage over allogenic AFSCs, which may be mediated by a
reduced fetal immune response.
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